NRX Pharmaceuticals (NRXP) Profit After Tax Growth (3y) (2020 - 2026)
NRX Pharmaceuticals (NRXP) Profit After Tax Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 71.02% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 17.25% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.89% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 37.44% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -29.12% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 59.34% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -38.56% |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | -23.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.67% |
| Dec 31, 2025 | 26.81% |
| Sep 30, 2025 | 13.44% |
| Jun 30, 2025 | -36.05% |
| Mar 31, 2025 | 25.72% |
| Dec 31, 2024 | 33.17% |
| Sep 30, 2024 | 64.75% |
| Jun 30, 2024 | -307.15% |
| Mar 31, 2024 | 36.49% |
| Dec 31, 2023 | 54.28% |
| Sep 30, 2023 | -5.51% |
| Jun 30, 2023 | -343.48% |
| Mar 31, 2023 | -51.34% |
| Dec 31, 2022 | -785.41% |
| Sep 30, 2022 | -437.68% |
| Jun 30, 2022 | -246.68% |
| Mar 31, 2022 | -318.97% |
| Sep 30, 2021 | -901.45% |
| Jun 30, 2021 | -147.59% |
| Mar 31, 2021 | -1,081.30% |